The combined use of batifiban, a synthetic platelet GP II b/IIIa receptor antagonist, and an- tithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation （NSTE） acute corona...The combined use of batifiban, a synthetic platelet GP II b/IIIa receptor antagonist, and an- tithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation （NSTE） acute coronary syndrome （ACS） and those scheduled for percutaneous coronary intervention. To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted. Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents. Blood samples were collected at pre-specified time points. The evaluation index included the inhibition of platelet aggregation and pharmacokinetic parameters. The pharmacokinetic parameters of batifiban and batifiban coadministered with antithrombin agents showed no significant differences. The mean inhibition rate of platelet aggre- gation （%） suggested that neither batifiban alone nor antithrombin agents alone could provide such po- tent inhibition rate （〉80%） to obtain the best clinical efficacy, but they had a synergistic effect on plate- let inhibition. No serious adverse effects were observed. The results in these healthy subjects suggest that batifiban coadministrated with antithrombin agents could achieve optimum clinical treatment effect for patients with NSTE ACS, and also those scheduled for percutaneous coronary intervention.展开更多
该文首先简述中药质量控制技术现状、瓶颈问题及严峻的挑战,提出应改变以事后检验为主要手段而不重视过程管控的药品监管现象,扭转业界忽视发展制药过程管控技术的局面,重构中药产品质量控制技术体系;通过建立以制药过程管控为核心的中...该文首先简述中药质量控制技术现状、瓶颈问题及严峻的挑战,提出应改变以事后检验为主要手段而不重视过程管控的药品监管现象,扭转业界忽视发展制药过程管控技术的局面,重构中药产品质量控制技术体系;通过建立以制药过程管控为核心的中药质量控制技术和监管体系,从根本上解决质量控制技术落后、质量风险管控措施不力、产品质量声誉不高等中药行业重大现实问题,从而突破中成药产品质量可控性差等难关。围绕中药质量控制技术领域中的难点问题和薄弱环节,提议尽快构建具有中国原创特色的中药CMC(chemistry,manufacturing and controls)技术规则并推动其得到国际认可,同时设计了以临床疗效为导向、制造方式为主轴、过程控制为重点的中药CMC技术架构。根据中医药临床特色及中成药生产特点,建议将药物分析学与中药化学、中药药理学、制药工程学、控制工程学、管理工程学等学科相结合,创立中药质量控制工程学。进而,提出中药质量控制工程理论模型及数字制药工程方法学,阐述了显著提升中药标准、实现中药国际化战略目标的技术路径。展开更多
基金supported by National Science & Technology Specific Projects in the 12th Five-Year Plan of China (No.2011ZX09302-002-01)
文摘The combined use of batifiban, a synthetic platelet GP II b/IIIa receptor antagonist, and an- tithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation （NSTE） acute coronary syndrome （ACS） and those scheduled for percutaneous coronary intervention. To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted. Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents. Blood samples were collected at pre-specified time points. The evaluation index included the inhibition of platelet aggregation and pharmacokinetic parameters. The pharmacokinetic parameters of batifiban and batifiban coadministered with antithrombin agents showed no significant differences. The mean inhibition rate of platelet aggre- gation （%） suggested that neither batifiban alone nor antithrombin agents alone could provide such po- tent inhibition rate （〉80%） to obtain the best clinical efficacy, but they had a synergistic effect on plate- let inhibition. No serious adverse effects were observed. The results in these healthy subjects suggest that batifiban coadministrated with antithrombin agents could achieve optimum clinical treatment effect for patients with NSTE ACS, and also those scheduled for percutaneous coronary intervention.
文摘该文首先简述中药质量控制技术现状、瓶颈问题及严峻的挑战,提出应改变以事后检验为主要手段而不重视过程管控的药品监管现象,扭转业界忽视发展制药过程管控技术的局面,重构中药产品质量控制技术体系;通过建立以制药过程管控为核心的中药质量控制技术和监管体系,从根本上解决质量控制技术落后、质量风险管控措施不力、产品质量声誉不高等中药行业重大现实问题,从而突破中成药产品质量可控性差等难关。围绕中药质量控制技术领域中的难点问题和薄弱环节,提议尽快构建具有中国原创特色的中药CMC(chemistry,manufacturing and controls)技术规则并推动其得到国际认可,同时设计了以临床疗效为导向、制造方式为主轴、过程控制为重点的中药CMC技术架构。根据中医药临床特色及中成药生产特点,建议将药物分析学与中药化学、中药药理学、制药工程学、控制工程学、管理工程学等学科相结合,创立中药质量控制工程学。进而,提出中药质量控制工程理论模型及数字制药工程方法学,阐述了显著提升中药标准、实现中药国际化战略目标的技术路径。
